Floatz logo

cd19/cd22-car-transduced t cells

Lymphoma, Non-Hodgkin

National Cancer Institute (NCI)Cell therapyPhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

98 Active assets in the Lymphoma, Non-Hodgkin cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BB
Cytosin-Arabinosid
Mwanasha Merrill, MD
Phase 3BB
METHOTREXATE
Sun Yat-sen University
Phase 3BB
Plerixafor
Thomas Jefferson University
Phase 4BB
Obinutuzumab
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

cd19/cd22-car-transduced t cells is also rated in:

B-precursor ALLDormant
CCC
Indicative ·
48 / 100
View asset →
Leukemia, Lymphocytic, B CellDormant
CCC
Indicative ·
48 / 100
View asset →
B-AllDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →